Ellen Isaacs Fights Against Purdue Pharma’s Bankruptcy Plan
Long-time advocate against the opioid epidemic, Ellen Isaacs, is taking a stand against the bankruptcy plan of Purdue Pharma, the pharmaceutical company responsible for manufacturing OxyContin. Isaacs, who tragically lost her son to a drug overdose, has been actively raising awareness about the dangers of opioids and seeking justice for the role Purdue Pharma and the Sackler family played in the crisis.
The bankruptcy plan proposed by Purdue Pharma includes a settlement in which the Sackler family, who owns the company, will contribute billions of dollars to combat the opioid crisis. However, it also includes a controversial release that provides legal protection to the Sacklers, shielding them from civil lawsuits.
While the bankruptcy plan was approved by 95% of the victims, several states, Canadian municipalities, indigenous tribes, and individuals voted against it due to concerns over the legal protections for the Sackler family. As a result, the case, known as Harrington v. Purdue Pharma, is now being reviewed by the Supreme Court.
The central issue before the court is whether opponents of federal bankruptcy agreements can be bound by releases that protect entities who have not declared bankruptcy themselves, such as the Sacklers. Represented by the Justice Department, the U.S. Trustee has argued that the release for the Sacklers violates federal law and has urged the Supreme Court to reject the plan.
The case has sharply divided victims of the opioid crisis. Some believe that the bankruptcy plan is the best way to hold Purdue Pharma accountable and provide relief to victims, while others, like Ellen Isaacs, oppose the plan. They seek the opportunity to hold the Sackler family accountable in civil court.
The Supreme Court’s decision in the Harrington v. Purdue Pharma case could have significant implications for future bankruptcy cases and the use of releases to protect corporate owners and decision-makers from liability. A decision on the case is expected to be made by the summer, and it will undoubtedly shape the further course of actions against Purdue Pharma and its owners.
As Ellen Isaacs continues to fight for justice and for the victims of the opioid crisis, the outcome of this case will be closely watched by both those directly affected by the crisis and those concerned with corporate accountability and responsibility.
“Infuriatingly humble tv expert. Friendly student. Travel fanatic. Bacon fan. Unable to type with boxing gloves on.”